ARDT Stock Forecast & Price Target

Ardent Health is supported by improving operating execution, with 3Q26 adjusted admissions up 2.9% year over year, ER visits turning positive, and urgent care visits rising 9%, all signaling healthy demand across its mid-sized urban markets. Cost discipline is also strengthening, as SWB declined 4.3% to 39.9% of revenue, contract labor fell 45% to 2.0% of SWB, and professional fee growth slowed to 7.4%, helping drive a 3Q EBITDA beat and strong cash generation of $122MM. The company’s $766MM cash balance, 2.5x lease-adjusted net leverage, durable supplemental Medicaid tailwinds, and M&A optionality in attractive growth markets create a credible path to further margin expansion and shareholder value creation.

Ardent Health is viewed negatively because its upside depends heavily on near-term ambulatory expansion and organic volume growth, yet the downside scenarios assume those initiatives fail as patient engagement efforts falter. In that case, 2027E adjusted EBITDAR would run about 10% below current estimates with valuation compressing to 4.5x, while a similar 2028E view still implies a multiple near 5.3x, both well below peer levels. The company also faces material headwinds from Medicare and ACA reimbursement risk, labor cost and availability pressures, claims-denial and professional-fee pressure, and geographic concentration, with 34% of beds in Texas and 27% in Oklahoma.